RaQualia Pharma Inc. Logo

RaQualia Pharma Inc.

Develops and out-licenses innovative small molecule drug compounds.

4579 | T

Overview

Corporate Details

ISIN(s):
JP3967150008
LEI:
Country:
Japan
Address:
名古屋市中村区名駅南一丁目21番19号

Description

RaQualia Pharma Inc. is a research and development-focused pharmaceutical company that specializes in the discovery and development of innovative small molecule compounds. The company's primary activities involve conducting exploratory research to identify novel drug candidates and advancing them through preclinical and clinical studies. Its business model centers on creating value by out-licensing the intellectual property of these compounds to other pharmaceutical companies for final development and commercialization. A key product originating from its research is tegoprazan (K-CAB®), a potassium-competitive acid blocker used for treating gastroesophageal reflux disease and other acid-related conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2020-05-15 08:30
四半期報告書-第13期第1四半期(令和2年1月1日-令和2年3月31日)
Japanese ZIP 154.2 KB
2020-03-27 07:02
有価証券報告書-第12期(平成31年1月1日-令和1年12月31日)
Japanese ZIP 1.1 MB
2019-11-08 07:16
四半期報告書-第12期第3四半期(2019/07/01-2019/09/30)
Japanese ZIP 174.5 KB
2019-08-09 08:14
四半期報告書-第12期第2四半期(2019/04/01-2019/06/30)
Japanese ZIP 179.1 KB
2019-05-14 08:23
四半期報告書-第12期第1四半期(2019/01/01-2019/03/31)
Japanese ZIP 197.9 KB
2019-03-26 03:47
有価証券報告書-第11期(平成30年1月1日-平成30年12月31日)
Japanese ZIP 1.1 MB
2018-11-09 07:20
四半期報告書-第11期第3四半期(2018/07/01-2018/09/30)
Japanese ZIP 172.7 KB
2018-08-10 09:07
四半期報告書-第11期第2四半期(2018/04/01-2018/06/30)
Japanese ZIP 182.8 KB
2018-05-11 09:33
四半期報告書-第11期第1四半期(2018/01/01-2018/03/31)
Japanese ZIP 176.3 KB
2018-03-30 03:03
有価証券報告書-第10期(平成29年1月1日-平成29年12月31日)
Japanese ZIP 1.0 MB
2017-11-10 07:32
四半期報告書-第10期第3四半期(2017/07/01-2017/09/30)
Japanese ZIP 164.1 KB
2017-11-10 07:25
訂正四半期報告書-第10期第2四半期(2017/04/01-2017/06/30)
Japanese ZIP 134.1 KB
2017-08-10 08:17
四半期報告書-第10期第2四半期(2017/04/01-2017/06/30)
Japanese ZIP 181.3 KB
2017-05-15 02:55
四半期報告書-第10期第1四半期(2017/01/01-2017/03/31)
Japanese ZIP 165.1 KB
2017-03-31 03:55
有価証券報告書-第9期(2016/01/01-2016/12/31)
Japanese ZIP 974.3 KB

Automate Your Workflow. Get a real-time feed of all RaQualia Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RaQualia Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RaQualia Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.